

**Appendix 4E**  
**Preliminary Final Report**  
**For the 4 months ended 31 August 2007**

**RESULTS FOR ANNOUNCEMENT TO THE MARKET**

*(All comparisons to the year ended 30 April 2007)*

	<b>31 August 2007</b>	<b>30 April 2007</b>
	<b>\$'000</b>	<b>\$'000</b>
Revenue	940,303	2,648,989
Profit before interest, tax, depreciation & associates	17,209	22,444
Profit before interest, tax & associates	11,608	7,074
Profit/(loss) before tax & associates	4,335	(13,298)
Loss before tax	(1,247)	(15,843)
Loss from ordinary activities after tax attributable to members	(2,598)	(11,270)
	<b>Amount per share</b>	<b>Franked amount per share</b>
<b>Dividend information</b>		
Interim dividend per share – cents	-	-
Final dividend per share - cents	-	-
Total dividends per share for the period - cents	-	-

	<b>31 August 2007</b>	<b>30 April 2007</b>
Net tangible asset backing per share	\$0.72	\$0.76

**Change of financial year end to 31 August 2007**

The Company received approval from the Australian Securities & Investment Commission (ASIC) to transition to a financial year ended 31 August. As a result, this preliminary final report represents a transitional financial period for the four months to 31 August 2007.

*In thousands of AUD*

		<b>Consolidated</b>	
	<b>Note</b>	<b>Four months ended 31 August 2007</b>	<b>Year ended 30 April 2007</b>
Revenue		940,303	2,648,989
Cost of sales		(834,400)	(2,321,396)
<b>Gross profit</b>		<b>105,903</b>	<b>327,593</b>
Other income	3	9,668	12,513
Warehousing and distribution expenses		(29,772)	(86,052)
Marketing and sales expense		(54,423)	(172,456)
Administration and general expenses		(19,768)	(74,524)
<b>Results from operating activities</b>		<b>11,608</b>	<b>7,074</b>
Financial income	5	1,592	3,478
Financial expenses	5	(8,865)	(23,850)
<b>Net financing costs</b>		<b>(7,273)</b>	<b>(20,372)</b>
<b>Profit/(loss) before tax and results from associates</b>		<b>4,335</b>	<b>(13,298)</b>
Share of loss of associates	8	(5,582)	(2,545)
<b>Loss before tax</b>		<b>(1,247)</b>	<b>(15,843)</b>
Income tax expense		(1,351)	4,358
<b>Loss for the period</b>		<b>(2,598)</b>	<b>(11,485)</b>
<b>Attributable to:</b>			
Equity holders of the parent		(2,598)	(11,270)
Minority interest		-	(215)
<b>Loss for the period</b>		<b>(2,598)</b>	<b>(11,485)</b>
<b>Loss per share for profit attributable to the ordinary equity holders of the Company (cents per share):</b>			
Basic loss per share	7	(1.0)	(4.4)
Diluted loss per share	7	(1.0)	(4.4)

*In thousands of AUD*

	<b>Consolidated</b>	
	<b>Four months ended 31 August 2007</b>	<b>Year ended 30 April 2007</b>
Foreign exchange translation differences	(2,758)	2,626
Effective portion of changes in fair value of cash flow hedges	1,085	(362)
<b>Net expense recognised directly in equity</b>	<b>(1,673)</b>	<b>2,264</b>
<b>Loss for the period</b>	<b>(2,598)</b>	<b>(11,485)</b>
<b>Total recognised income and expense for the period</b>	<b>(4,271)</b>	<b>(9,221)</b>
<b>Attributable to:</b>		
Equity holders of the parent	(4,271)	(9,006)
Minority interest	-	(215)
<b>Total recognised income and expense for the period</b>	<b>(4,271)</b>	<b>(9,221)</b>

Other movements in equity arising from transactions with owners as owners are set out in Note 9.

*In thousands of AUD*

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 August 2007</b>	<b>30 April 2007</b>
<b>Assets</b>			
Cash and cash equivalents	10	16,064	21,315
Trade and other receivables		148,347	120,461
Inventories		301,030	256,492
Income tax receivable		8,901	14,068
Assets classified as held for sale	6	14,456	-
<b>Total current assets</b>		<b>488,798</b>	<b>412,336</b>
Receivables		98,525	124,844
Investments accounted for using the equity method	8	23,847	26,330
Deferred tax assets		11,119	12,284
Property, plant and equipment		77,345	76,046
Intangible assets		208,649	217,524
<b>Total non-current assets</b>		<b>419,485</b>	<b>457,028</b>
<b>Total assets</b>		<b>908,283</b>	<b>869,364</b>
<b>Liabilities</b>			
Bank overdraft	10	6,506	6,693
Trade and other payables		463,953	423,807
Interest-bearing loans and borrowings		2,202	1,831
Employee benefits		13,444	13,134
Provisions		4,110	656
<b>Total current liabilities</b>		<b>490,215</b>	<b>446,121</b>
Trade and other payables		3,950	4,233
Interest-bearing loans and borrowings		2,873	2,650
Employee benefits		1,845	2,762
Provisions		2,248	2,363
<b>Total non-current liabilities</b>		<b>10,916</b>	<b>12,008</b>
<b>Total liabilities</b>		<b>501,131</b>	<b>458,129</b>
<b>Net assets</b>		<b>407,152</b>	<b>411,235</b>
<b>Equity</b>			
Issued capital		419,499	419,499
Reserves		(44)	1,441
Retained earnings		(12,303)	(9,705)
<b>Total equity</b>	9	<b>407,152</b>	<b>411,235</b>

**Statement of Cash Flows**

Australian Pharmaceutical Industries Limited and Controlled Entities

Preliminary Final Report

For the four months ended 31 August 2007

*In thousands of AUD*

	<i>Note</i>	<b>Consolidated</b>	
		<b>Four months ended 31 August 2007</b>	<b>Year ended 30 April 2007</b>
<b>Cash flows from operating activities</b>			
Cash receipts from customers		1,006,447	2,961,285
Cash paid to suppliers and employees		(1,018,503)	(2,883,828)
Cash generated from operations		(12,056)	77,457
Interest received	5	1,592	3,478
Interest paid	5	(8,865)	(23,850)
Income tax refund / (paid)		5,189	(7,185)
<b>Net cash from operating activities</b>		<b>(14,140)</b>	<b>49,900</b>
<b>Cash flows from investing activities</b>			
Proceeds from sale of property, plant and equipment		2,486	2,338
Acquisition of property, plant and equipment		(9,166)	(19,272)
Deferred consideration receivable		7,918	5,460
Loans to pharmacies		(297)	(389)
Loans to associates		-	(7,327)
Proceeds from disposal of subsidiary, net of cash disposed		8,500	4,000
Acquisition of subsidiary, net of cash acquired		(1,000)	-
Acquisition of investments in associates		-	(1,949)
Payment for intangibles		(124)	(6,364)
<b>Net cash from investing activities</b>		<b>8,317</b>	<b>(23,503)</b>
<b>Cash flows from financing activities</b>			
Proceeds from/(payment for) interest bearing note (securitised receivable)		-	(32,543)
Proceeds from borrowings		795	-
Payment of finance lease liabilities		(200)	(1,434)
Repayment of depositors' loans		-	1
Dividends paid	9	-	(7,720)
<b>Net cash from financing activities</b>		<b>595</b>	<b>(41,696)</b>
Net decrease in cash and cash equivalents		(5,228)	(15,299)
Cash and cash equivalents at 1 May		14,622	30,060
Effect of exchange rate fluctuations on cash held		164	(139)
<b>Cash and cash equivalents at the end of the period</b>	10	<b>9,558</b>	<b>14,622</b>

## 1. SIGNIFICANT ACCOUNTING POLICIES

Australian Pharmaceutical Industries Limited (the 'Company') is a company domiciled in Australia. The preliminary final report of the Company for the four months ended 31 August 2007 comprises the Company and its subsidiaries (together referred to as the 'consolidated entity') and the consolidated entity's interest in associates and jointly controlled entities.

### (a) Statement of compliance

The preliminary final report has been prepared in accordance with the measurement requirements of Australian Accounting Standards ('AASBs') adopted by the Australian Accounting Standards Board ('AASB') for the purpose of fulfilling the consolidated entity's obligation under the Australian Stock Exchange listing rules.

### (b) Basis of preparation

The preliminary final report is presented in Australian dollars.

The preliminary final report is prepared on the historical cost basis except that the following assets and liabilities are stated at their fair value: derivative financial instruments and financial instruments classified as available-for-sale.

The accounting policies have been applied consistently and a full description of the accounting policies adopted by the consolidated entity may be found in the consolidated entity's full financial report.

## 2. SEGMENT REPORTING

Segment information is presented in respect of the consolidated entity's business and geographical segments. The primary format, business segments, is based on the consolidated entity's management and internal reporting structure.

Inter-segment pricing is determined on an arm's length basis.

Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly loyalty program costs, and corporate assets and expenses.

Segment capital expenditure is the total cost incurred during the year to acquire segment assets that are expected to be used for more than one year.

### **Business Segments**

The consolidated entity comprises the following operating divisions:

#### ***Pharmacy Distribution***

Australia – Distribution of pharmaceutical and medical products to pharmacies, provider of retail services to pharmacy customers, loans and leases to pharmacy customers.

#### ***Retailing***

Australia – The purchase and sale of various health, beauty and lifestyle products within the retail industry in Australia.

#### ***Manufacturing***

Australia – Owner of rights to pharmaceutical medicines manufactured by related parties.

New Zealand – Manufacture of pharmaceutical medicines and consumer toiletries.

## 2. SEGMENT REPORTING (continued)

*In thousands of AUD*

	DISTRIBUTION		RETAILING		MANUFACTURING				ELIMINATIONS		CONSOLIDATED	
	AUSTRALIA		AUSTRALIA		AUSTRALIA		NEW ZEALAND					
	Four months to 31/08/2007	Year ended 30/04/2007	Four months to 31/08/2007	Year ended 30/04/2007	Four months to 31/08/2007	Year ended 30/04/2007	Four months to 31/08/2007	Year ended 30/04/2007	Four months to 31/08/2007	Year ended 30/04/2007	Four months to 31/08/2007	Year ended 30/04/2007
<b>Revenue</b>												
External segment sales	730,302	1,962,927	172,845	566,030	884	6,248	11,005	35,417	-	-	915,036	2,570,622
External segment services	6,235	26,458	19,032	51,909	-	-	-	-	-	-	25,267	78,367
Internal segment sales	-	-	-	-	2,473	3,500	1,358	7,166	(3,831)	(10,666)	-	-
<b>Total segment revenue</b>	<b>736,537</b>	<b>1,989,385</b>	<b>191,877</b>	<b>617,939</b>	<b>3,357</b>	<b>9,748</b>	<b>12,363</b>	<b>42,583</b>	<b>(3,831)</b>	<b>(10,666)</b>	<b>940,303</b>	<b>2,648,989</b>
<b>Segment result</b>	9,966	27,581	7,603	24,654	304	(166)	148	147	-	-	18,021	52,216
Unallocated income												
Significant Expenses											-	(30,533)
Unallocated expenses											(6,413)	(14,609)
Profit before financing costs											11,608	7,074
Net financing costs											(7,273)	(20,372)
Share of profit of associates											(5,582)	(2,545)
Gain/(loss) on sale of discontinued operation											-	-
(Loss)/Profit before tax											(1,247)	(15,843)
Income tax expense											(1,351)	4,358
<b>Net (loss)/ profit</b>											<b>(2,598)</b>	<b>(11,485)</b>
Depreciation & amortisation	2,914	8,296	2,258	6,028	-	-	429	1,046	-	-	5,601	15,370
<b>Assets</b>												
<b>Segment assets</b>	570,386	546,308	365,696	371,475	21,963	26,579	56,536	73,146	(134,055)	(174,474)	880,526	843,034
Equity accounted investments	23,847	26,330	-	-	-	-	-	-	-	-	23,847	26,330
Unallocated corporate assets	-	-	-	-	-	-	-	-	-	-	3,910	-
<b>Consolidated total assets</b>	<b>594,233</b>	<b>572,638</b>	<b>365,696</b>	<b>371,475</b>	<b>21,963</b>	<b>26,579</b>	<b>56,536</b>	<b>73,146</b>	<b>(134,055)</b>	<b>(174,474)</b>	<b>908,283</b>	<b>869,364</b>
<b>Liabilities</b>												
<b>Segment liabilities</b>	398,819	386,504	201,778	211,919	14,107	18,848	14,768	14,740	(134,055)	(174,474)	495,417	457,537
Unallocated corporate liabilities	-	-	-	-	-	-	-	-	-	-	5,714	592
<b>Consolidated total liabilities</b>	<b>398,819</b>	<b>386,504</b>	<b>201,778</b>	<b>211,919</b>	<b>14,107</b>	<b>18,848</b>	<b>14,768</b>	<b>14,740</b>	<b>(134,055)</b>	<b>(174,474)</b>	<b>501,131</b>	<b>458,129</b>
<b>Capital Expenditure</b>	422	3,045	6,632	22,128	-	-	2,112	2,319	-	-	9,166	27,492

*In thousands of AUD*

	Australia		New Zealand		Consolidated	
	Four months to 31/08/2007	Year ended 30/04/2007	Four months to 31/08/2007	Year ended 30/04/2007	Four months to 31/08/2007	Year ended 30/04/2007
<b>Secondary reporting – Geographical segments</b>						
External segment revenue by location of customers		927,940		2,606,406		42,583
Segment assets by location of assets		851,747		796,218		73,146
Capital Expenditure		7,054		25,173		2,319

### 3. OTHER INCOME

<i>In thousands of AUD</i>	<b>Consolidated</b>	
	<b>Four months ended 31 August 2007</b>	<b>Year ended 30 April 2007</b>
Net gain on disposal of stores, property, plant and equipment	7,725	12,261
Gain on sale of business	1,943	252
	9,668	12,513

### 4. SIGNIFICANT EXPENSES

<i>In thousands of AUD</i>		
Termination & redundancy costs	-	3,449
Financial year 2006 completion costs	-	4,075
Corporate expenses	-	3,244
Joint venture and divestment costs	-	3,946
Retail shrinkage & stock-take costs	-	7,656
Pharmacy inventory obsolescence	-	8,163
	-	30,533

### 5. FINANCE INCOME AND EXPENSE

<i>In thousands of AUD</i>		
Interest income on bank deposits	(1,592)	(3,478)
Interest expense on financial liabilities measured at amortised cost	8,865	23,850
Net financing costs	7,273	20,372

### 6. ASSETS HELD FOR SALE

Price Attack, which forms part of the Retail segment is presented as a disposal group held for sale following the commitment of the Group's management during the period to plan to sell this business. Efforts to sell the disposal group have commenced and a sale is expected by October 2007. At 31 August 2007 the disposal group comprised assets of \$14,456,000.

#### Assets classified as held for sale

<i>In thousands of AUD</i>	<b>Consolidated 31 August 2007</b>
Property, plant & equipment	996
Brand name & goodwill	13,460
	14,456

## 7. EARNINGS PER SHARE

### Basic earnings per share

The calculation of basic earnings per share at 31 August 2007 was based on the loss attributable to ordinary shareholders of \$2,597,511 (April 2007: loss of \$11,270,000) and a weighted average number of ordinary shares outstanding during the four months ended 31 August 2007 of 257,346,455 (April 2007: 257,346,455), calculated as follows:

#### Profit attributable to ordinary shareholders

	Note	Consolidated	
		Four months ended 31 August 2007	Year ended 30 April 2007
<i>In thousands of AUD</i>			
Loss attributable to ordinary shareholders		(2,598)	(11,270)

#### Weighted average number of ordinary shares

*In thousands of shares*

Issued ordinary shares at 1 May	9	257,346	257,346
Weighted average number of ordinary shares at the end of the period		257,346	257,346

#### Diluted earnings per share

The calculation of diluted earnings per share at 31 August 2007 was based on loss attributable to ordinary shareholders of \$2,597,511 (April 2007: loss of \$11,270,000), and a weighted average number of ordinary shares outstanding during the four months ended 31 August 2007 of 257,479,318 (April 2007: 257,346,455), calculated as follows:

#### Profit attributable to ordinary shareholders (diluted)

	Note	Consolidated	
		Four months ended 31 August 2007	Year ended 30 April 2007
<i>In thousands of AUD</i>			
Loss attributable to ordinary shareholders (diluted)		(2,598)	(11,270)

#### Weighted average number of ordinary shares (diluted)

*In thousands of shares*

Weighted average number of ordinary shares at the end of the period	9	257,346	257,346
Effect of potential ordinary shares on issue		133	-
Weighted average number of ordinary shares (diluted) at the end of the period		257,479	257,346

#### Earnings per share for continuing and discontinued operations

##### Basic earnings per share

*In cents*

From continuing operations		(1.0)	(4.4)
----------------------------	--	-------	-------

##### Diluted earnings per share

*In cents*

From continuing operations		(1.0)	(4.4)
----------------------------	--	-------	-------

For the four months ended 31 August 2007, earnings per share for continuing and discontinued operations have been calculated using the same figures as earnings per share.

## 8. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

### Investments in associates and joint venture entities

The consolidated entity accounts for investments in associates and joint venture entities using the equity method.

The consolidated entity has the following investments in associates and joint venture entities:

Venture	Principal activities	Country	Reporting Date	Ownership	
				31 August 2007	30 April 2007
CH2 Holdings Pty Ltd	Hospital supplies distribution	Australia	30 June	45.3%	45.3%
Making Life Easy Pty Ltd	Operates mobility and independent living retail superstores	Australia	30 June	-	50.0%

#### CH2 Holdings Pty Ltd

During the year ended 30 April 2007, the consolidated entity reduced its ownership in CH2 Holdings Pty Ltd to 45.3% as a result of employees taking an equity stake. As part of this agreement the consolidated entity made a further investment of \$1,948,747 in this business.

#### Making Life Easy Pty Ltd

On the 2<sup>nd</sup> of July 2007, the consolidated entity acquired the remaining 50% of the shares in Making Life Easy Pty Ltd (MLE). As a result, MLE became a 100% owned subsidiary company from that date.

<i>In thousands of AUD</i>	Revenues 100%	Profit/(loss) 100%	Share of associates net profit/(loss) recognised	Net assets as reported by associates 100%	Share of associate's net assets equity accounted (including goodwill)
<b>For the four months ended August 2007</b>					
CH2 Holdings Pty Ltd	225,512	(5,479)	(2,482)	42,132	23,847
Making Life Easy Pty Ltd	4,529	(6,200)	(3,100)	-	-
	230,041	(11,679)	(5,582)	42,132	23,847
<b>For the year ended April 2007</b>					
CH2 Holdings Pty Ltd	652,565	(2,020)	(1,010)	47,688	26,330
Making Life Easy Pty Ltd	16,712	(3,070)	(1,535)	(4,513)	-
	669,277	(5,090)	(2,545)	43,175	26,330

### Results of associates

<i>In thousands of AUD</i>	Consolidated	
	Four months ended 31 August 2007	Year ended 30 April 2007
Share of associate loss before income tax	(6,646)	(2,978)
Share of income tax benefit	1,064	433
Share of associates net loss accounted for using the equity method	<u>(5,582)</u>	<u>(2,545)</u>

**Notes to the Preliminary Financial Report**

Australian Pharmaceutical Industries Limited and Controlled Entities

Preliminary Final Report

For the four months ended 31 August 2007

**9. CAPITAL AND RESERVES**

	Share Capital	Retained Earnings	Translation Reserve	Hedging Reserve	Equity Reserve	Total	Minority Interest	Total Equity
<i>In thousands of AUD</i>								
Balance at 1 May 2006	419,499	9,285	(838)	-	15	427,961	936	428,897
Disposals during the year	-	-	-	-	-	-	(721)	(721)
Total recognised income and expense	-	(11,270)	2,626	(362)	-	(9,006)	(215)	(9,221)
Dividends to shareholders	-	(7,720)	-	-	-	(7,720)	-	(7,720)
<b>Balance at 30 April 2007</b>	<b>419,499</b>	<b>(9,705)</b>	<b>1,788</b>	<b>(362)</b>	<b>15</b>	<b>411,235</b>	<b>-</b>	<b>411,235</b>
Balance at 1 May 2007	419,499	(9,705)	1,788	(362)	15	411,235	-	411,235
Equity settled transactions, net of tax	-	-	-	-	188	188	-	188
Total recognised income and expense	-	(2,598)	(2,758)	1,085	-	(4,271)	-	(4,271)
<b>Balance at 31 August 2007</b>	<b>419,499</b>	<b>(12,303)</b>	<b>(970)</b>	<b>723</b>	<b>203</b>	<b>407,152</b>	<b>-</b>	<b>407,152</b>

**Share capital**
**The Company  
Ordinary shares**
*In thousands of shares*

	31 August 2007	30 April 2007
Shares on issue at 1 May – fully paid	257,346	257,346
Shares on issue at the end of the period– fully paid	257,346	257,346

**Ordinary shares**

Holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at shareholders meetings.

In the event of a winding up of the Company, ordinary shareholders rank after all other creditors and are fully entitled to any proceeds of liquidation.

**Translation reserve**

The translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign operations where their functional currency is different to the presentation currency of the reporting entity, as well as from the translation of liabilities that hedge the Company's net investment in a foreign subsidiary.

**Equity reserve**

The equity reserve relates to share-based payment transactions measured at fair value.

**Hedging reserve**

The hedging reserve comprises the effective portion of the cumulative net change in the fair value of cash flow hedging instruments relating to hedged transactions that have not yet occurred.

## 9. CAPITAL AND RESERVES (continued)

### Dividends

Dividends recognised in the current period by the Company are:

<i>In thousands of AUD</i>	<b>Cents per share</b>	<b>Total amount</b>	<b>Franked / unfranked</b>	<b>Date of payment</b>
<b>Four months ended August 2007</b>				
Final 2007 ordinary	-	-	-	
Total amount	-	-		
<b>Year ended April 2007</b>				
Final 2006 ordinary	3.0	7,720	Franked	8 September 2006
Total amount		7,720		

Franked dividends declared or paid during the year ended 30 April 2007 were franked at the tax rate of 30%.

<i>In thousands of AUD</i>	<b>The Company</b>	
	<b>31 August 2007</b>	<b>30 April 2007</b>
<b>Dividend franking account</b>		
30 per cent franking credits available to shareholders of the Company for subsequent financial years	3,005	2,890

The above available amounts are based on the balance of the dividend franking account at year-end adjusted for:

- Franking credits that will arise from the payment of the current tax liabilities;
- Franking debits that will arise from the payment of dividends recognised as a liability at the year end;
- Franking credits that will arise from the receipt of dividends recognised as receivables by the tax consolidated group at the year end;
- Franking credits that the entity may be prevented from distributing in subsequent years, and
- Franking debits that will arise from receipt of the current income tax receivable.

The ability to utilise the franking credits is dependent upon there being sufficient available profits to declare dividends. As there are no profits available, no dividend can be declared.

## 10. CASH AND CASH EQUIVALENTS

<i>In thousands of AUD</i>	<b>Consolidated</b>	
	<b>31 August 2007</b>	<b>30 April 2007</b>
Cash and cash equivalents	16,064	21,315
Bank overdrafts repayable on demand	(6,506)	(6,693)
Cash and cash equivalents in the statement of cash flows	9,558	14,622

## 11. CONTINGENCIES

The directors are of the opinion that provisions are not required in respect of these matters, as it is not probable that a future sacrifice of economic benefits will be required or the amount is not capable of reliable measurement.

<i>In thousands of AUD</i>	<b>Notes</b>	<b>Consolidated</b>	
		<b>31 August 2007</b>	<b>30 April 2007</b>
Contingent liabilities considered remote			
Guarantee of bank facilities of pharmacy customers	i.	85,709	97,043
Contingent liability on termination of a director's service contract		750	710
Guarantee for property rentals	ii.	14,974	19,535
Contingent liability for potential ClubCard voucher redemptions	iii.	5,197	4,888

These guarantees are not secured.

- i. The Company has strict controls over the approval of guarantees of pharmacy customers and takes security over the assets of the relevant pharmacy.
- ii. The guarantee for property rentals represents guarantees on franchisee leases of premises.
- iii. The contingent liability for ClubCard voucher redemptions represents the value of vouchers issued and not redeemed or provided for. A provision has been recognised for potential voucher redemptions based on historical redemption notes.

Deferred consideration payable in respect of the acquisition of Synapse Finance Pty Ltd (Re: New Price Retail business) was calculated on 7 October 2007, 3 years from acquisition date. Under the terms of the agreement, as the API share price at that time did not exceed \$3.00, there is no further consideration payable.

## **Commentary on the Results for the Period**

The commentary on the results of the period is contained in the "August 2007 Results Presentation" dated 30th October 2007.

## **Annual Meeting**

The annual meeting will be held as follows:

Place	Menzies Hotel 14 Carrington Street, Sydney NSW
Date:	Tuesday, 18 December, 2007
Time:	2:00pm
Approximate date the annual report will be available:	7 December 2007

## **Compliance Statement**

1. The financial report is in the process of being audited.
2. The entity has a formally constituted audit committee.